M

Mayinglong Pharmaceutical Group Co Ltd
SSE:600993

Watchlist Manager
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Watchlist
Price: 28.41 CNY 0.07% Market Closed
Market Cap: 12.2B CNY

Mayinglong Pharmaceutical Group Co Ltd
Income from Continuing Operations

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Mayinglong Pharmaceutical Group Co Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
M
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Income from Continuing Operations
Â¥595.4m
CAGR 3-Years
5%
CAGR 5-Years
8%
CAGR 10-Years
12%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Income from Continuing Operations
Â¥4.8B
CAGR 3-Years
21%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Income from Continuing Operations
Â¥2.4B
CAGR 3-Years
-1%
CAGR 5-Years
8%
CAGR 10-Years
17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Income from Continuing Operations
Â¥7.5B
CAGR 3-Years
30%
CAGR 5-Years
5%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Income from Continuing Operations
Â¥5.2B
CAGR 3-Years
28%
CAGR 5-Years
1%
CAGR 10-Years
7%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Income from Continuing Operations
Â¥3.7B
CAGR 3-Years
N/A
CAGR 5-Years
244%
CAGR 10-Years
N/A
No Stocks Found

Mayinglong Pharmaceutical Group Co Ltd
Glance View

Market Cap
12.2B CNY
Industry
Pharmaceuticals

In the corridors of China's pharmaceutical industry, Mayinglong Pharmaceutical Group Co Ltd stands out with its roots deeply embedded in history while its branches stretch ambitiously into the future. Founded in 1582 during the Ming Dynasty, this firm has garnered a reputation for its innovative approach to traditional Chinese medicine. The company's evolution from an apothecary serving local communities to a publicly traded enterprise mirrors the dynamic growth of China itself. As the world became increasingly captivated by holistic health solutions, Mayinglong capitalized on its heritage of time-tested remedies, turning ancient formulations into modern products. Their flagship product, Mayinglong Hemorrhoid Ointment, is a renowned success, both domestically and internationally, symbolizing the company's unique ability to blend ancient wisdom with contemporary health needs. Mayinglong's business model thrives on a well-balanced portfolio that includes not only traditional Chinese medicines but also a growing pipeline of innovative pharmaceuticals and healthcare products. Leveraging state-of-the-art technology in their R&D centers, they develop new drugs and therapies that align with both modern health trends and the regulatory demands of global markets. The group's revenue streams are diversified across multiple segments, including over-the-counter products, prescription medications, and personal care items. With a vast distribution network both in China and abroad, Mayinglong benefits from scale and brand recognition. Their strategy is a testament to the harmonious merger of tradition and modernity, driving profitability through a deep understanding of consumer needs paired with scientific innovation.

Mayinglong Pharmaceutical Group Co Ltd Intrinsic Value
HIDDEN
Show

See Also

What is Mayinglong Pharmaceutical Group Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
595.4m CNY

Based on the financial report for Sep 30, 2025, Mayinglong Pharmaceutical Group Co Ltd's Income from Continuing Operations amounts to 595.4m CNY.

What is Mayinglong Pharmaceutical Group Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
12%

Over the last year, the Income from Continuing Operations growth was 21%. The average annual Income from Continuing Operations growth rates for Mayinglong Pharmaceutical Group Co Ltd have been 5% over the past three years , 8% over the past five years , and 12% over the past ten years .

Back to Top